Stockholders Approve Proposal One Clearing Way for Consummation of Merger RICHLAND, WASHINGTON – January 30, 2023 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the...
RICHLAND, WASHINGTON – January 12, 2023 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that the January 12th, 2023, adjourned Annual...
RICHLAND, WASHINGTON – December 14, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that the December 13th, 2022, Annual Meeting is...
Revenue Increased 12% Year-Over-Year Record Non-Prostate Brachytherapy Revenue Increased 28% Year-Over-Year RICHLAND, WASHINGTON – November 10, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering...
Conference Call is Thursday, November 10, 2022 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – October 31, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout...
RICHLAND, WA and CORALVILLE, IA – October 18, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, and Viewpoint Molecular Targeting, Inc., a radiopharmaceutical company developing precision lead-212-based...
RICHLAND, WASHINGTON – September 28, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it has entered into a definitive agreement to acquire Viewpoint Molecular Targeting, Inc. (Viewpoint)...
Conference Call is Wednesday, September 28 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – September 21, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call...
RICHLAND, WASHINGTON – June 21, 2022 – The growing body of information regarding Isoray, Inc.’s (NYSE American: ISR) Cesium-131 in treating prostate cancer was highlighted in two presentations at the just concluded American Brachytherapy Society’s annual conference...
RICHLAND, WASHINGTON – June 15, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a lunch symposium featuring Dr. Stephen J. Frank of the MD Anderson Cancer Center at the...
Revenue Increased 12% Year-Over-Year Record Non-Prostate Brachytherapy Revenue Increased 28% Year-Over-Year RICHLAND, WASHINGTON – May 10, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced its...
Conference Call is Tuesday, May 10, 2022 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – April 29, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call to...
Isoray to Participate in the Oppenheimer 32nd Annual Healthcare Conference RICHLAND, WASHINGTON – March 10, 2022 – Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy, today announced that Chief Executive Officer Lori...